HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma

Tissue Antigens

Volumn 64, Issue 1, 2004, Pages 84-87

  Luongo, V ^a   Pirozzi, G ^a   Caraco C ^a   Errico, S ^a   De Angelis, F ^a   Celentano, E ^a   Paino, F ^a   Chiofalo, M G ^a   Luongo, M ^a   Mozzillo, N ^a   Lombardi, M L ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NONE   (Italy)

Author keywords

HLA alleles; Melanoma

Indexed keywords

HLA A ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; SKIN TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; HLA ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; ITALY; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS;

EID: 3042699977     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-2815.2004.00250.x     Document Type: Article

References (22)

1. Lee JE, Reveille JD, Ross M, Platsoucas CD. HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer 1994: 59: 510-3.
2. Lee JE, Lu M, Mansfield PF, Platsoucas CD, Reveille JD, Ross M. Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer stage I or II. Cancer 1996: 78: 758-63.
3. Lee JE, Abdalla J, Porter GA et al. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon γ levels and disease recurrence in melanoma patients. Ann Surg Oncol 2002: 9: 587-93.
4. Bateman AC, Turner SJ, Theaker JM, Howell WM. HLA-DQB1*0303 and *0301 alleles influence susceptibility to and prognosis in cutaneous malignant melanoma in the British Caucasian population. Tissue Antigens 1998: 52: 67-73.
5. Lombardi ML, Mercuro O, Pirozzi G et al. Molecular analysis of HLA DRB1 and DQB1 polymorphism in Italian melanoma patients. J Immunother 1998: 21: 435-9.
6. Lulli P, Grammatico P, Brioli G, Catricalà C. HLA-DR and DQ alleles in Italian patients with melanoma. Tissue Antigens 1998: 51: 276-80.
7. Muto M, Ohmura A, Nakano J et al. HLA class I polymorphism and the susceptibility to malignant melanoma. Tissue Antigens 1996: 47: 447-9.
8. Lowes MA, Dunckley H, Watson N et al. Regression of melanoma, but not keratoacanthoma, is associated with increased HLA-B22 and decreased HLA-B27 and HLA-DR1. Melanoma Res 1999: 9: 539-44.
9. Balch CM, Cascinelli N. The new melanoma staging system. Tumori 2001: 87: 64-8.
10. Lombardi ML, Mercuro O, Ruocco V et al. Common human leucocyte antigens in Pemphigus vulgaris and Pemphigus foliaceus Italian patients. J Invest Dermatol 1999: 113: 107-10.
11. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992: 39: 225-35.
12. Hildesheim A, Schiffman M, Scott DR et al. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev 1998: 7: 1035-41.
13. Matsumoto K, Yasugi T, Nakagawa S et al. Human papilloma virus type 16, E6 variants and HLA class II alleles among Japanese women with cervical cancer. Int J Cancer 2003: 106: 919-22.
14. Marsh SGE, Bodmer JG, Albert ED et al. Nomenclature for factors of the HLA system, 2000. Eur J Immunogenet 2001: 28: 377-424.
15. Balch CM, Soong S, Ross MI. Long term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0-4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000: 7: 87-97.
16. Ibrahim ELC, Aractingi S, Allory Y et al. Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. Int J Cancer 2004: 108: 243-50.
17. Ferrone CR, Panageas KS, Busam K et al. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel node status. Ann Surg Oncol 2002: 9: 637-45.
18. Berretta F, Butler RH, Diaz G et al. Detailed analysis of the effects of Glu/Lys B69 human leukocyte antigen DP polymorphism on peptide-binding specificità. Tissue Antigens 2003: 62: 459-71.
19. Luiten RM, Demote N, Tine J, van der Bruggen P, Mage A. A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens 2000: 56: 77-81.
20. Reynolds SR, Celis E, Sette A et al. Identification of HLA-A*03, A*11 and B*07-restricted associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. J Immunol Methods 2000: 244: 59-67.
21. Zarour HM, Kirkwood JM. Melanoma vaccines: early progress and future promises. Semin Cutan Med Surg 2003: 22: 68-75.
22. Sugimura K, Asakura H, Mizuki N et al. Analysis of genes within the HLA region affecting susceptibility to ulcerative colitis. Hum Immunol 1993: 36: 112-8.